Classical and recent advances in the treatment of inflammatory bowel diseases

Autor(es)

Sales-Campos, H. ^[1] ; Basso, P. J. ^[2] ; Alves, V. B. F. ^[1] ; Fonseca, M. T. C. ^[2] ; Bonfa, G. ^[2] ; Nardini, V. ^[1] ; Cardoso, C. R. B. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14049 Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Imunol & Bioquim, BR-14049 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 48, n. 2, p. 96-107, FEB 2015.
• Citações Web of Science: 23

Resumo

Crohn's disease (CD) and ulcerative colitis (UC) are intestinal disorders that comprise the inflammatory bowel diseases (IBD). These disorders have a significant effect on the quality of life of affected patients and the increasing number of IBD cases worldwide is a growing concern. Because of the overall burden of IBD and its multifactorial etiology, efforts have been made to improve the medical management of these inflammatory conditions. The classical therapeutic strategies aim to control the exacerbated host immune response with aminosalicylates, antibiotics, corticosteroids, thiopurines, methotrexate and anti-tumor necrosis factor (TNF) biological agents. Although successful in the treatment of several CD or UC conditions, these drugs have limited effectiveness, and variable responses may culminate in unpredictable outcomes. The ideal therapy should reduce inflammation without inducing immunosuppression, and remains a challenge to health care personnel. Recently, a number of additional approaches to IBD therapy, such as new target molecules for biological agents and cellular therapy, have shown promising results. A deeper understanding of IBD pathogenesis and the availability of novel therapies are needed to improve therapeutic success. This review describes the overall key features of therapies currently employed in clinical practice as well as novel and future alternative IBD treatment methods. (AU)

• Processo FAPESP: 10/20162-7 - Papel do eixo hipotálamo-pituitária adrenal e glicocorticóides exógenos na modulação da resposta imune na doença inflamatória intestinal
• Beneficiário: Cristina Ribeiro de Barros Cardoso
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores